Current and Future Drug Treatments for Female Sexual Dysfunctions
Background
Female Sexual Dysfunctions (FSDs) encompass a range of conditions, including Hypoactive Sexual Desire Disorder (HSDD), Genitopelvic Pain/Penetration Disorder (GPPD), and Female Orgasmic Disorder (FOD), significantly impacting women's quality of life. Despite their high prevalence, effective and widely accessible pharmacotherapies remain limited, often leading to underdiagnosis and undertreatment. This review addresses the critical need to summarize the current landscape of approved and emerging drug treatments for FSDs and identify future directions in this evolving field.
Results
The review identified two FDA-approved drugs specifically for HSDD: Flibanserin (a serotonin 1A receptor agonist and 2A receptor antagonist) and Bremelanotide (a melanocortin 4 receptor agonist). Flibanserin demonstrated modest improvements in sexual desire and distress in premenopausal women, typically administered as 100 mg daily. Bremelanotide showed similar efficacy, administered as an on-demand 1.75 mg subcutaneous injection. For dyspareunia (painful intercourse) associated with Vulvovaginal Atrophy (VVA), Ospemifene (a selective estrogen receptor modulator) was highlighted as an effective oral treatment, typically 60 mg daily, significantly reducing pain. The field is actively exploring novel targets beyond traditional hormonal approaches, with several promising non-hormonal compounds in various stages of development for diverse FSDs, indicating a significant shift in research focus. Additionally, the review discussed the off-label use of hormonal therapies like DHEA and testosterone for certain FSDs, noting their potential benefits but also the need for more robust, long-term safety data and standardized dosing protocols.
Why It Matters
This review highlights the growing but still limited pharmacotherapeutic options for FSDs, emphasizing the significant unmet medical need for millions of women globally. The emergence of non-hormonal treatments and a shift towards personalized medicine approaches offers new hope for more effective and tailored interventions. Further research into novel mechanisms and the development of drugs for specific FSD subtypes could lead to improved clinical outcomes and enhanced quality of life for affected individuals. Future steps involve advancing promising compounds through Phase II and III human trials and integrating these pharmacotherapies into a multidisciplinary care model.